Fig. 6.

Antitumor efficacy of AMPG in HCC mouse model bearing HepG2 cells. A Representative fluorescence (ECH@AMPG in red) in HepG2 cell subcutaneous injection-induced xenograft tumor model at 3, 6, 12, and 24 h after intravenous injection of ECH@AMPG (5 mg/kg/day). B–J Xenograft mice 4 weeks post-injection with ECH (5 mg/kg/day), AMPG (5 mg/kg/day), or ECH@AMPG (5 mg/kg/day). B HepG2 cell survival. Tumor (C) volume and (D) weight. E, F TUNEL-positive cells. G–I IHC staining of UBR5 and AXIN1. J Xenograft mouse tumors showing UBR5, AXIN1, LDHA, PKM2, Survivin, C-myc, and β-catenin expression. Scale bars, 50 μm. **P < 0.01, ***P < 0.001